Tom

About Tom Rauscher

This author has not yet filled in any details.
So far Tom Rauscher has created 16 blog entries.

Three Levels of Competitive Intelligence Research

2020-10-28T15:01:00+00:00October 28th, 2020|Categories: Blog|

Competitive intelligence is an extremely valuable step of any new drug or indication launch. From providing insight into a crowded market to guiding allocation of budget, this research is beneficial no matter what stage of the launch process you’re in. However, “competitive intelligence” is simply the broad, overarching term. In reality, it encompasses a variety of research tactics ranging from high-level, free information gathering to granular, high-investment research [...]

Article Round Up: How the COVID-19 Outbreak is Impacting the Pharmaceutical Industry When Launching a New Drug

2020-10-14T18:57:40+00:00October 14th, 2020|Categories: Blog, COVID-19|

The COVID-19 pandemic is unprecedented and unpredictable. Nevertheless, we are remaining flexible as we continue to support pharmaceutical manufacturers and their life-changing work. Regardless of which stage you’re at in the drug development journey — from clinical trials to loss of exclusivity — we’re trusted pharma consultants who have the insight, expertise, and solutions needed to keep you moving. Since March, our team of experts have tracked the pandemic’s impact [...]

Why are some drug launches successful and some aren’t?

2020-10-05T03:17:19+00:00October 5th, 2020|Categories: Blog|

The launch of a new drug is a complex process. With so many factors playing into the final outcome, it may seem impossible to predict whether or not any given launch will be a success. While it’s true that unforeseen circumstances may impact the result of a launch — such as the start of a global pandemic — there are telling signs that can indicate launch performance. [...]

ROI & Rx Dollars At Risk Calculator

2020-10-07T13:47:46+00:00October 2nd, 2020|Categories: Resource|

Use this tool to calculate your potential ROI and Rx Dollars at Risk. Input your WAC$ and Average Treatment Time below. Calculate Your Rx Dollars at Risk Your Medication CALCULATE Please note; our assumptions are based on our latest data. We do not save any of the information you input into this tool. Results [...]

6 Examples of When Competitive Intelligence Should Be a Top Priority

2020-09-30T19:04:08+00:00September 25th, 2020|Categories: Blog|

The pharma industry can be complicated, but the more intel you have – market or competitive, the better you’ll be able to make decisions that lead you to success. Understanding what’s worked for your competitors, what hasn’t, where they’re going, and what opportunities exist gives you a clear advantage — whether you’re breaking into the market or fighting to defend your market share. While these insights can be [...]

5 Key Takeaways When Launching a New Drug

2020-09-15T15:52:07+00:00September 11th, 2020|Categories: Blog|

For those launching their first product, the process can be incredibly daunting – but if you know what to look for, both the successes and the failures can help guide your launch strategy. With over 215+ new product launches since our inception, we’ve got a firm grasp on what works and what doesn’t. Here are 5 key takeaways we’ve developed over the years. [...]

New White Paper: Pathways of Care, Shifting Financial Risk and Value Frameworks – Where is the Oncology Market Heading?

2020-07-19T18:50:37+00:00July 19th, 2020|Categories: Blog|

Historically, the management of oncology drugs in the U.S. has remained relatively hands-off, despite high budget impact. However, the situation may be changing. Recently, there has been discussion around new management tools, shifting of financial risk, and the influence of value frameworks. In June 2020, Two Labs conducted a panel with payers, hematology and oncology providers, and representatives from several big pharma and small biotech companies with oncology [...]

Why Manufacturers Launching Specialty Drugs Need Trade Management

2020-06-22T17:27:24+00:00June 19th, 2020|Categories: Blog|

Launching a drug isn’t easy. All manufacturers, no matter the classification of product they create, face challenges on the journey to bring their drug to market. However, due to the nature of their dose form, complex storage needs, stability requirements, and costs, manufacturers launching specialty drugs must often navigate more hurdles than those dealing with a traditional retail product. Not appropriately planning for or inaccurately handling these hurdles [...]

COVID-19 Q&A: How will the outbreak impact DSCSA

2020-06-03T14:26:01+00:00June 3rd, 2020|Categories: COVID-19|Tags: |

COVID-19 is impacting the healthcare system in a way we’ve never seen before, and pharmaceutical manufacturers are facing new challenges at rapid speeds. To help keep you informed, we’re releasing a special Q&A series with our experts to discuss the virus’s impact on each stage of the launch journey. Today, we spoke with DSCSA and Serialization Services Manager Michael Rowe about the effect of COVID-19 [...]

COVID-19 Q&A: How will the outbreak impact U.S. pharmaceutical marketing and promotions

2020-05-19T15:03:20+00:00May 19th, 2020|Categories: COVID-19|Tags: |

COVID-19 is impacting the healthcare system in a way we’ve never seen before, and pharmaceutical manufacturers are facing new challenges at rapid speeds. To help keep you informed, we’re releasing a special Q&A series with our experts to discuss the virus’s impact on each stage of the development journey. Today, we spoke with David Ward, Vice President for EHRx Solutions, Sara Stricker, Manager at CEEK [...]

Go to Top